Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Evolva (EV-035 Series)

M&A STATUS
M&A LATEST DEAL TYPE
$70.5M LATEST DEAL AMOUNT
Description

Provider of antibiotics. The business unit is an anti-bacterial programme which includes broad-spectrum antibiotic GC-072, which is being developed with US government bio-defense funding.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
  • Reinach
  • Switzerland
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Evolva (EV-035 Series)’s full profile, request a free trial.

Evolva (EV-035 Series) Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Merger/Acquisition 17-Dec-2014 $70.5M 000.00 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Evolva (EV-035 Series) Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Evolva VC-Backed Company Majority 000 0000 000000 0